- Email: [email protected]
Special Notice Regarding Case Reports
J AM ACAD DERMATOL
Patel et al 1017
VOLUME 60, NUMBER 6
112. Bachmeyer C, Thioliere B, Khosrotehrani K, Cattan E. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 2006;56:169. 113. Nair B, Raval G, Mehta P. TNF-a inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4. 114. Meyboom RH, Star K, Bate J, Savage R, Edwards R. TNF-a inhibitors and leukemia: international pharmacovigilance reports. Drug Safety 2008;31:445-7. 115. Hurley MY, George MN, Leonardi CL, Frater JL. A transient benign lymph node-based proliferation of T-cells stimulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists. Diagn Pathol 2008;3:13-8. 116. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD301 Tcell lymphoma in a patient with psoriasis treated with cyclosporine and infliximab. Br J Dermatol 2003;149:170-3. 117. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005;352:351-61. 118. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97. 119. Kang BK, Kim TS. Targeting cytokines of the interleukin12 family in autoimmunity. Current Med Chem 2006;13: 1149-56. 120. Kastelstein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-42. 121. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008;128:1064-7. 122. Langowski JL, Xhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumor incidence and growth. Nature 2006;442:461-5.
123. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000;165:2665-70. 124. US Food and Drug Administration CDER 2008 Meeting Documents, Dermatologic & Ophthalmic Drugs Advisory Committee. June 17 and 18, 2008; transcripts. 125. Jacobsson L, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8. 126. Dixon WG, Watson KD, Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor a therapy. Arthritis Rheum 2007;56:2905-12. 127. Jacobsson L, Turesson C, Nilsson JA. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5. 128. Geborek P, Bladstrom A, Turreson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factors do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703. 129. Maruani A, Wiezbicka E, Machet MC, Abdallah-Loft M, de Muret A, Machet L. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007;57:S69-71. 130. Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol 2007;56:686-90. 131. Miyazaki T, Fujimake K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 2007;82:1106-9.
Patel et al 1017
VOLUME 60, NUMBER 6
112. Bachmeyer C, Thioliere B, Khosrotehrani K, Cattan E. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 2006;56:169. 113. Nair B, Raval G, Mehta P. TNF-a inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4. 114. Meyboom RH, Star K, Bate J, Savage R, Edwards R. TNF-a inhibitors and leukemia: international pharmacovigilance reports. Drug Safety 2008;31:445-7. 115. Hurley MY, George MN, Leonardi CL, Frater JL. A transient benign lymph node-based proliferation of T-cells stimulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists. Diagn Pathol 2008;3:13-8. 116. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD301 Tcell lymphoma in a patient with psoriasis treated with cyclosporine and infliximab. Br J Dermatol 2003;149:170-3. 117. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005;352:351-61. 118. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97. 119. Kang BK, Kim TS. Targeting cytokines of the interleukin12 family in autoimmunity. Current Med Chem 2006;13: 1149-56. 120. Kastelstein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-42. 121. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008;128:1064-7. 122. Langowski JL, Xhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumor incidence and growth. Nature 2006;442:461-5.
123. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000;165:2665-70. 124. US Food and Drug Administration CDER 2008 Meeting Documents, Dermatologic & Ophthalmic Drugs Advisory Committee. June 17 and 18, 2008; transcripts. 125. Jacobsson L, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8. 126. Dixon WG, Watson KD, Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor a therapy. Arthritis Rheum 2007;56:2905-12. 127. Jacobsson L, Turesson C, Nilsson JA. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5. 128. Geborek P, Bladstrom A, Turreson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factors do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703. 129. Maruani A, Wiezbicka E, Machet MC, Abdallah-Loft M, de Muret A, Machet L. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007;57:S69-71. 130. Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol 2007;56:686-90. 131. Miyazaki T, Fujimake K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 2007;82:1106-9.